Search

This article examines the impact of the COVID-19 pandemic on endoscopic pituitary surgery at a pituitary center of excellence. The study compared patients who underwent surgery before the pandemic (January 2015 to March 2020) with those who had surgery during the pandemic (March 2020 to September 2022). The results showed that patients who presented during the pandemic tended to be more frail and have more comorbidities. They were also more likely to have larger adenomas and require additional surgical approaches. Despite these changes, the length of stay and readmission rate remained stable, indicating the safety of the procedure during the pandemic. [Extracted from the article]

This article discusses the outcomes of the endoscopic endonasal approach (EEA) for nonfunctional pituitary adenomas (NFPAs) in elderly patients. The study involved a retrospective review of NFPAs in patients aged 65 and older who underwent EEA between 2007 and 2022 at a single medical center. The results showed that EEA was a safe and effective option for NFPA resection in elderly patients, with high rates of visual recovery postoperatively and acceptable rates of gross total resection (GTR). The study also identified risk factors for progression and subtotal resection, but found no associations between postoperative complications and age or frailty scores. [Extracted from the article]

This article, published in the Journal of Neurological Surgery, introduces a novel outcome metric called the 30-day hospitalization ratio (HR) for patients with pituitary adenomas. The metric combines the length of stay and readmission rates within a 30-day period to provide a comprehensive measure of the economic burden of treatment. The study analyzed the clinical records of 468 patients who underwent endoscopic endonasal surgery for pituitary adenoma. Factors associated with a high HR included high preoperative ASA scores, postoperative lumbar drain placement, intradural extension, and employment status. Understanding these risk factors can lead to personalized monitoring and care, ultimately reducing burden and improving outcomes. [Extracted from the article]

This article, published in the Journal of Neurological Surgery, examines the impact of frailty on surgical outcomes in patients with Cushing's disease (CD). The study analyzed data from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) and found that mild frailty independently predicted outcomes after transsphenoidal surgery for CD. Mildly frail patients had longer hospital stays and were more likely to be discharged to skilled nursing facilities. The study suggests that assessing frailty could be useful for preoperative risk stratification and prognostication in CD patients. [Extracted from the article]

This article explores the use of radiomic feature analysis to predict overall survival and progression-free survival after surgery in patients with skull base chordomas. The study extracted radiomic features from preoperative MRI scans and used unsupervised analysis to identify distinct groups based on these features. The results showed that the radiomic features were able to model overall survival and progression-free survival, and were also associated with genetic markers commonly used in clinical decision-making. The authors suggest that radiomics-based imaging biomarkers could be a noninvasive and cost-effective way to personalize care for patients with skull base chordomas. [Extracted from the article]

This article discusses the establishment of a national pituitary surgical research platform called RAPID, which aims to improve patient care and surgical outcomes for pituitary disorders. The initial focus of the collaboration is on Cushing's disease. The study provides an overview of the patient cohort, surgical outcomes, and lays the foundation for future research. The data collected from nine academic pituitary centers shows that 528 patients with Cushing's disease were treated by 26 neurosurgeons from 2003 to 2023. The report highlights insights into surgical outcomes and disease recurrence rates across different surgeons and environments. The collaboration is expected to advance the standard of care for patients with pituitary disorders. [Extracted from the article]

This article, published in the Journal of Neurological Surgery, examines the outcomes of patients with Crooke cell adenomas (CCA) compared to those with corticotroph adenomas (sCTA), both of which are types of pituitary corticotroph adenomas found in patients with Cushing's disease. The study, which included 2,826 patients from 12 international centers, found that CCA patients had poorer endocrinologic outcomes compared to sCTA patients, despite having better local control rates and fewer residual tumors. The authors suggest that further research is needed to better understand CCA and develop more targeted treatment approaches. [Extracted from the article]

This article discusses the issue of unplanned hospital readmissions following trans-sphenoidal surgery for Cushing's disease. The study analyzed data from a multi-institutional database of patients who underwent this surgery between 2003 and 2023. The results showed that 10.3% of patients experienced unplanned readmissions, with the most common reasons being hyponatremia, CSF leak evaluation, headache/nausea, and epistaxis. The study also found that an increased number of chronic medical conditions and the need for a return to surgery were associated with a higher chance of unplanned readmission. The authors suggest strategies to mitigate these readmissions, such as fluid restriction and optimizing chronic medical conditions. [Extracted from the article]

This article, published in the Journal of Neurological Surgery, explores the factors that contribute to the recurrence of Cushing's disease (CD) after transsphenoidal surgery. The study analyzed data from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) database, which included 383 CD patients. The results showed that patients who experienced recurrence had a longer postoperative hospital stay, larger tumor volumes, and a higher rate of failed prior treatment. Younger age and the absence of cavernous sinus invasion were identified as potential protective factors against recurrence. The findings suggest that early detection and treatment of tumors may improve outcomes for CD patients. [Extracted from the article]

Objective  Previous work categorized skull base chordoma (SBC) into three genetic risk groups based on 1p36 and homozygous 9p21(p16) deletions, accounting for a wide variability in prognosis (A = low-risk, B = intermediate-risk, C = high-risk). However, it remains unclear how these groups could guide management. Study Design  By integrating surgical outcome and adjuvant radiation (AdjXRT) information with genetic data on 152 tumors, we sought to develop an evidence-based management algorithm for SBC. Results  Gross total resections (GTRs) were associated with improved progression free survival (PFS) in all genetic groups. For Group C tumors, GTR and AdjXRT independently contributed to PFS (multivariate Cox proportional hazard ratio [HR] = 0.14, p  = 0.002, and HR = 0.40, p  = 0.047, respectively). For Group B tumors, AdjXRT improved outcomes only when GTR was not feasible (log-rank p  = 0.008), but not following GTR (log-rank p  = 0.54). However, 24 of 25 Group A tumors underwent GTR, and AdjXRT for these did not confer any benefit (log-Rank p  = 0.285). The high GTR rates in Group A could be explained by smaller tumor sizes (mean = 0.98cc/4.08cc/4.92cc for Group A/B/C, respectively, p  = 0.031) and lack of invasiveness. Group A tumors were also more frequently diagnosed in young people (p  = 0.002) as asymptomatic lesions (p  = 0.001), suggesting that they could be precursors to tumors in higher risk groups. Conclusion  Genotypic grouping by 1p36 and homozygous 9p21(p16) deletions can predict prognosis in SBC and guide management. GTR remains the cornerstone of SBC treatment and can be sufficient without AdjXRT in low and intermediate risk tumors. Low-risk tumors are associated with a less invasive phenotype, which makes them more amenable to GTR. [ABSTRACT FROM AUTHOR]